“Biologics and Synthetic Disease-Modifying Drugs Protective Against Anterior Uveitis in Axial Spondylarthritis Patients”

https://pubmed.ncbi.nlm.nih.gov/38116697

The study found that biologics and synthetic disease-modifying drugs, including anti-TNF mAbs, anti-IL17, and JAKi, appear to be protective against anterior uveitis events in axial spondylarthritis patients, with no significant differences in risk between treatments.